Harimaya Atsushi, Yokota Shin-ichi, Sato Kiyoshi, Himi Tetsuo, Fujii Nobuhiro
Department of Otolaryngology, Sapporo Medical University School of Medicine, S-1, W-16, Chuo-ku, Sapporo, Hokkaido 060-8543, Japan.
J Infect Chemother. 2008 Jun;14(3):223-7. doi: 10.1007/s10156-008-0604-5. Epub 2008 Jun 24.
Recently, the frequency of isolation of beta-lactamase-negative ampicillin resistant (BLNAR) strains of Haemophilus influenzae in Japanese children has been increasing rapidly. Drug resistance in BLNAR strains is associated with mutations of the fts I gene, which encodes penicillin-binding protein 3. In the otolaryngological field, only a few reports have been available concerning fts I gene mutations in BLNAR. We investigated the prevalence of fts I gene mutations, by polymerase chain reaction (PCR) genotyping, in H. influenzae isolates from the upper respiratory tracts of children in the Sapporo district, Japan. When the isolates were classified according to PCR genotyping, 34 (44.2%) of 77 isolates were beta-lactamase-negative ampicillin-sensitive (g-BLNAS), 8 (10.4%) were g-low-BLNAR, 30 (39.0%) were g-high-BLNAR, 2 (2.6%) were beta-lactamase-positive ampicillin-resistant (g-BLPAR), and 3 (3.9%) were beta-lactamase-positive ampicillin/clavulanic acid-resistant (g-high-BLPACR). Mutations in the fts I gene were generally parallel to ampicillin susceptibility, and were frequently observed in children who were 7 years or younger. Of the beta-lactams tested, cefditoren showed the strongest inhibition of H. influenzae isolates, and it inhibited g-BLNAR and g-BLPACR. This study revealed a remarkably high prevalence of fts I gene mutations (g-BLNAR and g-BLPACR) in our district. Furthermore, a regional difference in the prevalence of fts I gene mutations was observed even at the district level.
最近,日本儿童中流感嗜血杆菌β-内酰胺酶阴性氨苄西林耐药(BLNAR)菌株的分离频率迅速上升。BLNAR菌株中的耐药性与编码青霉素结合蛋白3的ftsI基因突变有关。在耳鼻咽喉科领域,关于BLNAR中ftsI基因突变的报道较少。我们通过聚合酶链反应(PCR)基因分型,调查了日本札幌地区儿童上呼吸道分离出的流感嗜血杆菌中ftsI基因突变的流行情况。根据PCR基因分型对分离株进行分类时,77株分离株中34株(44.2%)为β-内酰胺酶阴性氨苄西林敏感(g-BLNAS),8株(10.4%)为g-低BLNAR,30株(39.0%)为g-高BLNAR,2株(2.6%)为β-内酰胺酶阳性氨苄西林耐药(g-BLPAR),3株(3.9%)为β-内酰胺酶阳性氨苄西林/克拉维酸耐药(g-高BLPACR)。ftsI基因突变通常与氨苄西林敏感性平行,且在7岁及以下儿童中频繁出现。在所测试的β-内酰胺类药物中,头孢妥仑对流感嗜血杆菌分离株的抑制作用最强,它能抑制g-BLNAR和g-BLPACR。本研究揭示了我们地区ftsI基因突变(g-BLNAR和g-BLPACR)的患病率非常高。此外,即使在地区层面也观察到ftsI基因突变患病率存在区域差异。